The addition of a selective Cx43 channel inhibitor increased the sensitivity of human O-6-methylguanine-DNA methyltransferase (MGMT)-deficient and temozolomide (TMZ)-resistant GBM cells to TMZ treatment [15]. This evidence concerns the gene MGMT and glioblastoma.